<DOC>
	<DOCNO>NCT01493271</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multi-center study evaluate safety effect RO5093151 intraocular pressure patient ocular hypertension open angle glaucoma . Patients randomize receive oral dos RO5093151 placebo twice daily . The anticipated time study treatment 7 day possibility extend 28 day .</brief_summary>
	<brief_title>A Study RO5093151 Patients With Ocular Hypertension Or Open Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Adult patient , least 21 year age , inclusive Diagnosis ocular hypertension primary open angle glaucoma least one eye Able participate willing give inform consent Presence extreme narrow angle complete partial closure Progressive retinal optic nerve disease cause glaucoma History sign penetrate ocular trauma Uncontrolled hypertension Clinically significant abnormality laboratory test result Positive test result hepatitis B , hepatitis C , HIV 1 2 Kidney disease dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>